BioCardia Q3 2023 Gaap EPS $(0.12), Inline, Sales $357.00K Beat $20.00K Estimate
Portfolio Pulse from saritha@benzinga.com
BioCardia (NASDAQ:BCDA) reported Q3 2023 GAAP EPS of $(0.12), meeting analyst consensus. This is a 29.41% increase over losses from the same period last year. The company's quarterly sales of $357.00K beat the analyst consensus estimate of $20.00K by 1.69K percent, marking a 68.40% increase over sales from the same period last year.
November 08, 2023 | 10:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioCardia's Q3 2023 results met analyst expectations for EPS and significantly exceeded sales estimates. This indicates a strong financial performance, which could positively impact the stock in the short term.
BioCardia's Q3 2023 results show a significant improvement in both earnings and sales compared to the same period last year. The company's EPS met analyst expectations, indicating stable financial management. Moreover, the sales significantly exceeded analyst estimates, suggesting strong demand for the company's products. This strong financial performance could boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100